Communication Crucial to Developing Non-Preagreed Endpoints: Expert

Clinical Trials Advisor
A A
The FDA and Vanda failed to agree on a prespecified primary endpoint for the new sleep disorder drug, tasimelteon, but that didn’t derail the company’s NDA.

To View This Article:

Login

Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00